Objective:To investigate the therapeutic effect of nicorandil combined with recombinant human brain natriuretic peptide(rhBNP)on acute myocardial infarction(AMI).Methods:A total of 90 AMI patients admitted Wuhu Second Peo-ples Hospital between January 2020 and June 2021 were selected and divided into control group(n=45,nicorandil therapy)and intervention group(n=45,nicorandil combined with rhBNP)according to random number table method.Both groups were treated for 1 week and then followed up for 6 months.Thrombolysis in myocardial infarction(TIMI)flow grade,left ventricular ejection fraction(LVEF),serum levels of C reactive protein(CRP),cystatin C(CysC),cardiac troponin Ⅰ(cTnⅠ)and N-terminal pro brain natriuretic peptide(NT-proBNP),and incidence of adverse drug reactions and adverse events during follow-up were compared between two groups.Results:Compared with patients in control group after treatment,those in intervention group had significant higher proportion of TIMI grade 3(13.33％vs.31.11％)and LVEF[(60.26±9.21)％vs.(66.83±4.23)％],and significant lower serum levels of CRP[(2.22±0.14)mg/L vs.(1.23±0.13)mg/L],CysC[(1.26±0.23)mg/L vs.(1.03±0.22)mg/L],cTnⅠ[(18.36±3.69)ng/ml vs.(12.26±3.22)ng/ml],NT-proBNP[(380.36±110.26)ng/L vs.(225.29±111.24)ng/L],and incidence of adverse events(31.11％vs.6.67％)during 6-month follow-up(P＜0.05 or＜0.01).We detected no significant difference in inci-dence of adverse drug reactions between two groups(P=0.502).Conclusion:Nicorandil combined with rhBNP can effec-tively improve the curative effect,heart function and inflammation,reduce the serum levels of cTnⅠ and NT-proBNP with good safety in patients with acute myocardial infarction,which is worthy of promotion.
维普
万方数据